Myomo launches MyoCare

10Jul

Myomo launches MyoCare

Portfolio News
Myomo announced today that it launched its MyoCare program for providing support to first-year users of its MyoPro powered brace.MyoCare offers expanded support to current and future clients who receive their MyoPro directly from the Cambridge, Mass.-based company, at no additional cost. Read more >>

Share this post

Related Posts

19May

Chronix’s ASCO presentation abstract disclosure

Chronix Biomedical, Inc., a developer of novel blood-based cancer molecular diagnostics, notes the formal disclosure of the abstract covering its... read more
15Dec

Boston Harbor Angels Awards Portfolio Companies at Annual Meeting

Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its... read more
27Jun

Inside Archer Roose’s non-traditional partnerships strategy

To develop more wine-drinking occasions, partnerships have proven to be key for the canned wine brand Archer Roose. Archer Roose,... read more
15May

Technology helps blind pastor see clearly for first time in 50 years

"My youngest son, Nathan, found out about eSight about a year ago. I had never heard of the company," said... read more
30Nov

Leading Canned Wine Brand Archer Roose Launches at Target

This Month, Archer Roose, one of the leading canned wine companies with Elizabeth Banks as its Chief Creative Officer, launches... read more
02Sep

Q&A: What you need to know about assistive eye wear for blind, visually impaired patients

According to the Optometrists Network, one in six adults older than 45 years and one in four older than 75... read more
28Sep

I Tried 18 Canned Wines — These Are the 7 Worth Drinking

Canned wines are often the most brilliant and low-waste alternative for when you just want a glass (or two) of... read more
01May

Myomo pioneering an IPO that includes small investors

You might consider it a “people’s IPO.” If the medical robotics company Myomo Inc. goes public this month, as planned, it... read more
19Apr

Pyramid Biosciences and GeneQuantum Healthcare Announce Preclinical Data for GQ1010, a Potential Best-In-Class TROP2-Targeted Antibody Drug Conjugate, at the 2023 AACR Annual Meeting

Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, and its partner... read more
13Jun

KnipBio Announces Significant Development in Lower-Cost Feedstock Solution for Aquafeed Protein

KnipBio, Inc. announced today a major development in its fermentation research that enables the company to produce its single cell... read more